31 May 2016

Interim loss at Amberley

AIM-quoted refugee from the Full List, Amberley Group, the former speciality mineral and chemical outfit now a shell company run by French entrepreneur Guy Naggar, lost 68,000 in the six months to October and is continuing to 'search for opportunities to create significant shareholder value in the long term'. Robert Tyerman reports.

Amberley, which raised 1 million at 10p plus warrants in August, says its net asset value at the end of October was 2.45 million, or 6.95p a share, including 2.3 million cash. In late October, the company bought contracts for difference over ten million shares in fully listed fibres, umbrellas and wall coverings group Chapelthorpe at an average price of 18.9p a share, against today's 20p.

Naggar says Amberley has looked at 'a number of potential investments, in both the public and private arena' and promises that 'shareholders will be kept informed of any major developments'. Positive news would be welcome indeed for investors who have seen the shares halve to 12p since 2000.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

A new Angle on cancer diagnostics

Medical device manufacturer Angle (AIM: AGL) has raised a further £10 million through a placing at 64.5p. Angle has an exciting technology which has recently registered its first commercial sales. This extra cash will help to accelerate its marketing efforts and advance the research projects being carried out in major cancer centres.

Motif Bio and the ticking timebomb

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double!

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait 

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media 

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

More News